<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400045</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2020-04</org_study_id>
    <nct_id>NCT04400045</nct_id>
  </id_info>
  <brief_title>Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome</brief_title>
  <official_title>Clinical Open-label Phase 2 Study of Low Dose Treosulfan Based Conditioning Regimen Efficacy in Hematopoietic Stem Cell Transplantation for Children With Nijmegen Breakage Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan
      based conditioning regimen in HSCT in Nijmegen breakage syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nijmegen breakage syndrome (NBS) is a DNA repair disorder. The only curative option for
      combine immunodeficiency in NBS is allogeneic hematopoietic stem cell transplantation (HSCT).
      Standard myeloablative conditioning regimens in DNA repair disorders lead to increased
      morbidity and mortality after HSCT. Low doses of alkylators are used to reduce toxicity
      rates, which, however, increase the risks of mixed chimerism and graft failure. The data of
      treosulfan usage in NBS are sparse. To evaluate the safety and efficacy of low dose
      treosulfan based conditioning regimen in NBS, treosulfan 21g/m2 in combination with
      fludarabine 150mg/mg, cyclophosphamide 40mg/kg, thymoglobulin (Genzyme) 5mg/kg and rituximab
      100mg/m2 will be used from day -6 to -1 day, followed by stem cell infusion. The primary
      endpoint is event-free survival, where graft failure, death, and malignancies are considered
      as events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years after HSCT</time_frame>
    <description>Events: graft failure, death, malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of engraftment</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of viral infections</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute graft versus host disease</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic graft versus host disease</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early organ toxicity</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of transplant related mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of long-term toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>malignancies, non-malignant complications</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Nijmegen Breakage Syndrome</condition>
  <arm_group>
    <arm_group_label>intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Treosulfan 21mg/m2 (days -6, -5, -4)</description>
    <arm_group_label>intervention/treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged â‰¥ 3 months and &lt; 21 years

          2. Patients diagnosed with NBS eligible for an allogeneic HSCT

          3. Signed written informed consent signed by a parent or legal guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry Balashov, MD, PhD</last_name>
    <phone>+74952876570</phone>
    <phone_ext>6534</phone_ext>
    <email>bala8@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Laberko, MD</last_name>
    <phone>74952876570</phone>
    <phone_ext>6223</phone_ext>
    <email>alexandra.laberko@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HSCT department</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Balashov, MD, PhD</last_name>
      <phone>+74952876570</phone>
      <phone_ext>6534</phone_ext>
      <email>bala8@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nijmegen Breakage Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

